Technical Analysis for APLI - Appili Therapeutics Inc

Grade Last Price % Change Price Change
C 0.040 14.29% 0.005
APLI closed up 14.29 percent on Friday, July 26, 2024, on 15 percent of normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline. The stock crossed above its 200 day moving average, improving its long-term outlook by crossing above that critical trendline.
Earnings due: Aug 9
*** please verify all earnings dates ***
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Up

Date Alert Name Type % Chg
Crossed Above 20 DMA Bullish 0.00%
Crossed Above 200 DMA Bullish 0.00%
Crossed Above 50 DMA Bullish 0.00%
MACD Bullish Signal Line Cross Bullish 0.00%
Expansion Pivot Buy Setup Bullish Swing Setup 0.00%
Wide Bands Range Expansion 0.00%
Jack-in-the-Box Bearish Bearish Swing Setup 14.29%
Narrow Range Bar Range Contraction 14.29%
Wide Bands Range Expansion 14.29%
Gapped Up Strength 14.29%

   Recent Intraday Alerts

Alert Time
Rose Above 10 DMA 1 day ago
Up 1 ATR 1 day ago
Up 5% 1 day ago
Up 3% 1 day ago
Up 2% 1 day ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Appili Therapeutics Inc Description

Appili Therapeutics Inc is a Canada-based anti-infective pharmaceutical development company. The Company focuses on identifying, acquiring and advancing therapeutics for infectious disease. The Company is engaged in developing strategies to develop new classes of antibiotics and anti-infectives to the clinic to improve treatment and health of patients suffering from infection. The Company has over two anti-infective programs, which include ATI-1501 and ATI-1503. The Company's ATI-1501 is a taste-masked treatment for clostridium difficile infection. The Company's ATI-1503 is an antibiotic with a potential to treat Gram-negative infections, such as Klebsiella pneumoniae. The Company’s agents focus on the therapeutics, including antivirals, antifungals, antiparasitics and antimicrobials, which can treat the hospital and community acquired infections caused by multi-drug resistant pathogens.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Health Pharma Pharmaceutical Clinic Drug Disease Bacteria Infection Antibiotic Antimicrobial Anti Infectives Antibiotics Organisms Antivirals Biocides Infections Infectious Disease

Is APLI a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 0.08
52 Week Low 0.025
Average Volume 147,064
200-Day Moving Average 0.038
50-Day Moving Average 0.037
20-Day Moving Average 0.037
10-Day Moving Average 0.035
Average True Range 0.004
RSI (14) 60.63
ADX 17.69
+DI 28.195
-DI 35.294
Chandelier Exit (Long, 3 ATRs) 0.035
Chandelier Exit (Short, 3 ATRs) 0.041
Upper Bollinger Bands 0.044
Lower Bollinger Band 0.030
Percent B (%b) 0.71
BandWidth 39.459
MACD Line -0.001
MACD Signal Line -0.001
MACD Histogram 0.0001
Fundamentals Value
Market Cap 2.49 Million
Num Shares 62.3 Million
EPS -0.15
Price-to-Earnings (P/E) Ratio -0.26
Price-to-Sales 280.78
Price-to-Book 3.58
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.048
Resistance 3 (R3) 0.047 0.043 0.046
Resistance 2 (R2) 0.043 0.041 0.044 0.046
Resistance 1 (R1) 0.042 0.040 0.043 0.043 0.045
Pivot Point 0.038 0.038 0.039 0.039 0.038
Support 1 (S1) 0.037 0.036 0.038 0.038 0.035
Support 2 (S2) 0.033 0.035 0.034 0.034
Support 3 (S3) 0.032 0.033 0.034
Support 4 (S4) 0.033